The Wnt/beta-catenin pathway as a novel therapeutic target to selectively inhibit pathological liver progenitor cells during chronic liver disease

被引：0
|
作者：
Pasic, S. [1 ]
Pohl, S. O. [1 ]
Olynyk, J. K. [2 ,3 ]
Tosh, D. [6 ]
Adams, L. A. [4 ,5 ]
Dharmarajan, A. [1 ]
Tirnitz-Parker, J. E. E. [1 ,5 ]
机构：
[1] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Perth, WA, Australia
[2] Fremantle Hosp, Perth, WA, Australia
[3] Fiona Stanley Hosp, Perth, WA, Australia
[4] Sir Charles Gairdner Hosp, Perth, WA, Australia
[5] Univ Western Australia, Sch Med & Pharmacol, Fremantle, WA, Australia
[6] Univ Bath, Ctr Regenerat Med, Bath, Avon, England
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：31 / 32
页数：2
相关论文
共 44 条
  • [1] Therapeutic targeting of liver progenitor cells in chronic liver disease via PRI-724 inhibition of the Wnt/beta-catenin pathway
    Shirolkar, G.
    Tiwari, J. Gogoi
    Carlessi, R.
    Adams, L.
    Olynyk, J.
    Tirnitz-Parker, N.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 32 - 33
  • [2] Regucalcin is a novel target of beta-catenin in liver
    Nejak-Bowen, Kari N.
    Zeng, Gang
    Monga, Satdarshan P. S.
    [J]. FASEB JOURNAL, 2007, 21 (06): : A1136 - A1136
  • [3] Ivermectin inhibits the Wnt/beta-catenin pathway via a novel therapeutic target molecule, IvBP
    Yonezawa, Honami
    Uehara, Yoshimasa
    Nishiya, Naoyuki
    [J]. CANCER SCIENCE, 2021, 112 : 894 - 894
  • [4] Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications
    Stergios A Polyzos
    Jannis Kountouras
    Athanasios D Anastasilakis
    Evangelos Terpos
    [J]. Hepatobiliary & Pancreatic Diseases International, 2023, 22 (04) : 437 - 438
  • [5] Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications
    Polyzos, Stergios A.
    Kountouras, Jannis
    Anastasilakis, Athanasios D.
    Terpos, Evangelos
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (04) : 437 - 438
  • [6] Reply to Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications
    Harini, Karthik Shree
    Ezhilarasan, Devaraj
    [J]. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (04) : 439 - 440
  • [7] Reply to “Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications”
    Karthik Shree Harini
    Devaraj Ezhilarasan
    [J]. Hepatobiliary & Pancreatic Diseases International, 2023, 22 (04) : 439 - 440
  • [8] Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling
    Liu, Qiuping
    Sun, Jinghui
    Luo, Qing
    Ju, Yang
    Song, Guanbin
    [J]. CURRENT STEM CELL RESEARCH & THERAPY, 2021, 16 (05) : 630 - 637
  • [9] Epidermal growth factor receptor:: A novel target of the Wnt/β-catenin pathway in liver
    Tan, XP
    Apte, U
    Micsenyi, A
    Kotsagrelos, E
    Luo, JH
    Ranganathan, S
    Monga, DK
    Bell, A
    Michalopoulos, GK
    Monga, SPS
    [J]. GASTROENTEROLOGY, 2005, 129 (01) : 285 - 302
  • [10] Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells
    Abrahamsson, Annelie
    Geron, Ifat
    Gotlib, Jason
    Durocher, Jeffrey
    Creusot, Remi
    Kavalerchik, Edward
    Goff, Daniel
    Fathman, C. G.
    Lilleberg, Stanley L.
    Giles, Francis
    Weissman, Irving
    Jamieson, Catriona
    [J]. BLOOD, 2006, 108 (11) : 605A - 605A
12345